Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Toceranib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB known ✓ | P09619 | 12/20 | 1.00 |
| ▸ | KDR known ✓ | P35968 | 10/20 | 1.00 |
| ▸ | KIT known ✓ | P10721 | 2/20 | 0.72 |
| ▸ | FGFR1 | P11362 | 8/20 | 1.00 |
| ▸ | TLK2 | Q86UE8 | 5/20 | 1.00 |
| ▸ | PRKAA1 | Q13131 | 8/20 | 0.76 |
| ▸ | PRKAA2 | P54646 | 7/20 | 0.76 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.73 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.73 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.73 |
| ▸ | HDAC7 | Q8WUI4 | 4/20 | 0.73 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.73 |
| ▸ | HDAC10 | Q969S8 | 4/20 | 0.73 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.73 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.73 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.73 |
| ▸ | HDAC9 | Q9UKV0 | 4/20 | 0.73 |
| ▸ | HDAC5 | Q9UQL6 | 4/20 | 0.73 |
| ▸ | PLK4 | O00444 | 3/20 | 0.72 |
| ▸ | DCLK1 | O15075 | 3/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Toceranib SCHEMBL1673439 | 1.00 | PDGFRB (1.00) | PDGFRBKDRFGFR1TLK2PRKAA1 | |
| Toceranib SCHEMBL29354429 | 1.00 | PDGFRB (1.00) | PDGFRBKDRFGFR1TLK2PRKAA1 | |
| Toceranib SCHEMBL29397832 | 0.97 | PDGFRB (0.95) | PDGFRBKDRFGFR1TLK2PRKAA1 | |
| SCHEMBL31672513 | 0.95 | PDGFRB (0.90) | PDGFRBKDRFGFR1TLK2PRKAA1 | |
| SCHEMBL2115759 | 0.95 | PDGFRB (0.90) | PDGFRBKDRFGFR1TLK2PRKAA1 | |
| SCHEMBL22649592 | 0.93 | PDGFRB (0.87) | PDGFRBKDRFGFR1TLK2PRKAA1 | |
| SCHEMBL5830182 | 0.93 | PDGFRB (1.00) | PDGFRBKDRFGFR1TLK2PRKAA1 | |
| SCHEMBL22649596 | 0.93 | PDGFRB (0.86) | PDGFRBKDRFGFR1TLK2PRKAA1 | |
| SCHEMBL5830179 | 0.93 | PDGFRB (1.00) | PDGFRBKDRFGFR1TLK2PRKAA1 | |
| SCHEMBL31672543 | 0.91 | PDGFRB (0.83) | PDGFRBKDRFGFR1TLK2PRKAA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024254483-A9 | GENERATING POPULATIONS OF HUMAN BLOOD AND BLOOD VESSEL PROGENITORS FROM PLURIPOTENT STEM CELLS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2025-11-06 | — | — | WO | disclosed |
| US-20250154467-A1 | CREATION OF VASCULARIZED BIOLOGICAL STRUCTURES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2025-05-15 | — | — | US | disclosed |
| WO-2024254483-A2 | GENERATING POPULATIONS OF HUMAN BLOOD AND BLOOD VESSEL PROGENITORS FROM PLURIPOTENT STEM CELLS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2024-12-12 | — | — | WO | disclosed |
| WO-2023164242-A1 | CREATION OF VASCULARIZED BIOLOGICAL STRUCTURES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2023-08-31 | — | — | WO | disclosed |
| WO-2023130150-A2 | SYSTEMS, CELL LINES AND METHODS OF PRODUCING AND USING THE SAME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-07-06 | — | — | WO | disclosed |
| US-20230159894-A1 | GENERATING POPULATIONS OF HUMAN BLOOD AND BLOOD VESSEL PROGENITORS FROM PLURIPOTENT STEM CELLS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2023-05-25 | — | — | US | disclosed |
| WO-2022182982-A1 | METHODS FOR TREATING C-KIT KINASE MEDIATED DISEASES AND DISORDERS USING A SELECTIVE C-KIT KINASE INHIBITOR | THIRD HARMONIC BIO, INC. (US) | 2022-09-01 | — | — | WO | disclosed |
| CN-112716941-A | Pharmaceutical composition for treating canine mast cell tumor and preparation method thereof | 南京朗博特动物药业有限公司 | 2021-04-30 | — | — | CN | disclosed |
| US-20200338202-A1 | SHORT TAT OLIGOMERS FOR DRUG DELIVERY | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2020-10-29 | — | — | US | disclosed |
| US-10787640-B2 | Producing mesodermal cell types and methods of using the same | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2020-09-29 | — | — | US | disclosed |
| CN-1733303-A | Anticancer implantation agent containing blood vessel inhibitor | KONG QINGZHONG (CN) | 2006-02-15 | — | — | CN | disclosed |
| CN-1733302-A | Anticancer implantation agent | KONG QINGZHONG (CN) | 2006-02-15 | — | — | CN | disclosed |
| CN-1733300-A | Anticancer implantation agent | KONG QINGZHONG (CN) | 2006-02-15 | — | — | CN | disclosed |
| CN-1733304-A | Anticancer medicine composition containing blood vessel inhibitor | KONG QINGZHONG (CN) | 2006-02-15 | — | — | CN | disclosed |
| CN-1733301-A | Anticancer implantation agent | KONG QINGZHONG (CN) | 2006-02-15 | — | — | CN | disclosed |
| CN-1733306-A | Anticancer implantation agent containing blood vessel inhibitor and guanine similarities | KONG QINGZHONG (CN) | 2006-02-15 | — | — | CN | disclosed |
| US-20060009510-A1 | Method of synthesizing indolinone compounds | PHARMACIA & UPJOHN COMPANY LLC | 2006-01-12 | — | — | US | disclosed |
| CN-1686546-A | Anti entity tumour medicinal composition containing blood vessel inhibitor | SHANDONG LANJIN BIOLOG ENGINEE (CN) | 2005-10-26 | — | — | CN | disclosed |
| US-20050171357-A1 | Process for preparing indolinone derivatives | PHARMACIA & UPJOHN COMPANY | 2005-08-04 | — | — | US | disclosed |
| US-20030229229-A1 | Process for preparing indolinone derivatives | PHARMACIA & UPJOHN COMPANY | 2003-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171357-A1 | Process for preparing indolinone derivatives | CYP2B6, CYP2D6, CYP3A4 | PDGFRB 1410/4885KDR 3047/4885KIT 278/4885 |
| US-20200338202-A1 | SHORT TAT OLIGOMERS FOR DRUG DELIVERY | ACIN1, MYCBP, STAT3 | PDGFRB 1869/4885KDR 303/4885KIT 3967/4885 |
| US-20060009510-A1 | Method of synthesizing indolinone compounds | HCCS, ALDH18A1, MKI67 | PDGFRB 1602/4885KDR 2822/4885KIT 552/4885 |
| US-20030229229-A1 | Process for preparing indolinone derivatives | CYP2B6, CYP2D6, CYP3A4 | PDGFRB 1410/4885KDR 3047/4885KIT 278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.